Table 2.
Selected Clinical Trials of Exosomes for the Treatment of Diseases
| Cell Sources | Diseases | Phases | Status | Results | NCT Numbers |
|---|---|---|---|---|---|
| MSC | Severe COVID-19 | 2 | Completed | Improved clinical symptoms and oxygenation161 | NCT04493242 |
| Ascites | Colorectal Cancer | 1 | Completed | Safe, activated CD8+ CTL cells to exert specific anti-tumor immunity162 | Unknown |
| MSC | Acute Ischemic Stroke | 1, 2 | Recruiting | Unknown | NCT03384433 |
| MSC | Degenerative meniscus injury | 2 | Recruiting | Unknown | NCT05261360 |
| DC | Melanoma | 1 | Completed | Feasible, safe and mild effector T-cell response163 | Unknown |
| DC | Non-small cell lung cancer | 2 | Completed | Feasible and safe, enhanced anti-tumor response of NK cells, 32% patients achieved progression-free survival (4 months)164 | NCT01159288 |
| MSC | Chronic kidney disease | 2,3 | Completed | Safe and improved inflammatory immune response and improved overall renal function in patients with grade III–IV CKD165 | Unknown |
| MSC | OA | 1 | Recruiting | Unknown | NCT05060107 |
| MSC | AD | 1,2 | Recruiting | Unknown | NCT04388982 |